Kiora Pharmaceuticals Inc (KPRX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $5.44M
Last updated: Nov 17, 2026 at 11:04 AM ET
Kiora Pharmaceuticals Inc (KPRX) Financials: Revenue, Profit and Cash Flow
Kiora Pharmaceuticals reported revenue of $0 for the fiscal year ended Dec 31, 2025, down 100.0% from the year before. That year, net income was -$10.84M, operating cash flow was -$9.96M and free cash flow was -$10.07M. The quarter ended Sep 30, 2026 had revenue of $1.00M and net income of -$1.75M.
Revenue and Margins
The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of $12.83M.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $0 | -100.0% | N/A | N/A | N/A |
| Dec 2024 | $16.02M | N/A | 100.0% | 28.2% | 22.4% |
| Dec 2023 | $0 | N/A | N/A | N/A | N/A |
| Dec 2022 | $0 | N/A | N/A | N/A | N/A |
| Dec 2021 | $0 | -100.0% | N/A | N/A | N/A |
| Dec 2020 | $12.06K | -99.6% | 100.0% | -56960.5% | -56901.7% |
| Dec 2019 | $2.69M | +62.5% | 100.0% | -264.7% | -264.2% |
| Dec 2018 | $1.65M | +305.5% | 100.0% | -656.3% | -654.2% |
| Dec 2017 | $407.52K | -39.1% | 100.0% | -3572.7% | -3243.5% |
| Dec 2016 | $669.26K | N/A | 100.0% | -1994.3% | -1993.8% |
Income Statement
In the fiscal year ended Dec 2025, the company posted a net loss after a profit the year before. In the quarter ended Sep 2026, the company posted a net loss after a profit in the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $16.02M | $0 | $0 | $0 | $12.06K | $2.69M | $1.65M | $407.52K | $669.26K |
| Gross profit | $0 | $16.02M | $0 | $0 | $0 | $12.06K | $2.69M | $1.65M | $407.52K | $669.26K |
| Research and development | $10.78M | $7.84M | $4.03M | $3.45M | $5.35M | $3.57M | $5.39M | $8.06M | $10.33M | $8.42M |
| Operating income | -$12.83M | $4.51M | -$12.59M | -$12.31M | -$14.24M | -$6.87M | -$7.11M | -$10.84M | -$14.56M | -$13.35M |
| Net income | -$10.84M | $3.59M | -$12.51M | -$13.58M | -$13.77M | -$6.86M | -$7.10M | -$10.81M | -$13.22M | -$13.34M |
| EBITDA | N/A | N/A | -$12.53M | N/A | -$14.19M | -$6.84M | -$7.06M | -$10.81M | -$14.54M | -$13.34M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.00M | $0 | $0 | $0 | $0 | $0 | $0 | -$15.95M | $0 | $20.00K | $16.00M | $283.87K |
| Gross profit | $1.00M | $0 | $0 | -$10.51K | $0 | $0 | $0 | -$15.99M | $0 | $20.00K | $16.00M | -$7.93K |
| Operating income | -$1.69M | -$2.21M | -$2.51M | -$7.31M | -$794.44K | -$2.40M | -$2.33M | -$2.56M | -$3.60M | -$2.54M | $13.22M | -$2.12M |
| Net income | -$1.75M | -$2.08M | -$2.42M | -$6.52M | $26.81K | -$2.15M | -$2.19M | -$4.22M | -$3.41M | -$2.22M | $13.45M | -$2.27M |
Balance Sheet
As of Dec 2025, cash and equivalents exceeded short-term debt of $164.46K by $8.53M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $24.25M | $36.48M | $13.71M | $18.68M | $20.13M | $15.30M | $10.11M | $14.28M | $14.31M | $9.73M |
| Current assets | $21.75M | $29.71M | $4.74M | $7.68M | $8.99M | $1.73M | $4.32M | $8.48M | $8.46M | $4.15M |
| Cash and equivalents | $8.70M | $3.79M | $2.45M | $5.96M | $7.85M | $1.19M | $3.78M | $8.00M | $7.81M | $3.64M |
| Total liabilities | $8.13M | $10.72M | $7.60M | $7.27M | $5.55M | $5.57M | $3.49M | $5.34M | $16.23M | $10.06M |
| Short-term debt | $164.46K | $23.36K | $47.07K | $322.38K | $0 | $212.28K | $83.93K | $4.71K | $11.21K | $12.64K |
| Long-term debt | N/A | N/A | N/A | N/A | N/A | $278.19K | $0 | N/A | N/A | N/A |
| Shareholder equity | $16.13M | $25.76M | $6.11M | $11.41M | $14.58M | $9.73M | $6.62M | $8.94M | -$1.93M | -$329.42K |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $22.37M | $23.78M | $21.23M | $24.25M | $29.86M | $31.95M | $34.02M | $36.48M | $38.51M | $40.81M | $42.44M | $13.71M |
| Total liabilities | $7.08M | $6.92M | $7.29M | $8.13M | $7.45M | $9.82M | $10.32M | $10.72M | $8.48M | $7.71M | $7.54M | $7.60M |
| Cash and equivalents | $5.57M | $7.08M | $10.96M | $8.70M | $5.51M | $1.03M | $3.77M | $3.79M | $5.64M | $6.58M | $31.28M | $2.45M |
| Shareholder equity | $15.30M | $16.86M | $13.93M | $16.13M | $22.41M | $22.13M | $23.70M | $25.76M | $30.03M | $33.10M | $34.90M | $6.11M |
Cash Flow
Operating cash flow was negative in the fiscal year ended Dec 2025.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$9.96M | $8.56M | -$9.56M | -$10.43M | -$10.68M | -$7.32M | -$8.15M | -$10.84M | -$6.47M | -$8.41M |
| Capital expenditures | $110.79K | $6.26K | $0 | $0 | $63.87K | $20.08K | $0 | $20.00K | $37.00K | $11.00K |
| Free cash flow | -$10.07M | $8.55M | -$9.56M | -$10.43M | -$10.74M | -$7.34M | -$8.15M | -$10.86M | -$6.51M | -$8.42M |
| Dividends paid | N/A | N/A | N/A | N/A | N/A | N/A | $7.33K | N/A | N/A | N/A |
| Share repurchases | $0 | $1.19M | $813.32K | N/A | N/A | $498.69K | $97.08K | N/A | N/A | $323.81K |
| Investing cash flow | $14.43M | -$22.66M | $0 | $6.38K | -$157.02K | -$244.44K | $0 | -$270.00K | -$37.00K | $174.75K |
| Financing cash flow | $265.65K | $15.50M | $5.97M | $8.62M | $17.58M | $5.00M | $3.92M | $11.30M | $10.67M | $3.50M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$557.52K | -$1.89M | -$3.16M | -$2.18M | -$1.27M | -$3.80M | -$2.70M | -$2.25M | $920.06K | -$3.73M | $13.62M | -$2.58M |
| Capital expenditures | $355 | $23.46K | $5.02K | $78.16K | $431 | $32.20K | $0 | $45.03K | $3 | $51.29K | $5 | $1 |
| Free cash flow | -$557.87K | -$1.92M | -$3.17M | -$2.26M | -$1.27M | -$3.84M | -$2.70M | -$2.30M | $920.05K | -$3.78M | $13.62M | -$2.58M |
Frequently Asked Questions About KPRX
What is Kiora Pharmaceuticals' annual revenue?
Kiora Pharmaceuticals reported revenue of $0 for the fiscal year ended Dec 31, 2025.
How fast is Kiora Pharmaceuticals' revenue growing?
Revenue was down 100.0% for the fiscal year ended Dec 31, 2025 compared with the year before.
Is Kiora Pharmaceuticals profitable?
No. Kiora Pharmaceuticals reported net income of -$10.84M for the fiscal year ended Dec 31, 2025.
How much free cash flow does KPRX generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of -$9.96M minus capital expenditures of $110.79K produced free cash flow of -$10.07M.
How much debt does Kiora Pharmaceuticals have?
The balance sheet dated Dec 31, 2025 reported short-term debt of $164.46K and cash and equivalents of $8.70M.
KPRX pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors